Showing results (11-20 of 14) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Blood|August 30, 2023
Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapyJad Othman, Ing S Tiong, Jenny O'Nions, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2023
Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized TrialClaire N Harrison, Jyoti Nangalia, Rebecca Boucher, et al.Blood Neoplasia|June 2, 2025
Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHSJad Othman, Ho Pui Jeff Lam, Sarah Leong, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 2, 2026
Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk ModelCurtis A Lachowiez, Joshua F Zeidner, Jad Othman, et al.Pageof 2